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Context: Gastroenteritis (GE) remains the second major cause of death in the most vulnerable of the world’s populations. 
Potential treatments include the use of probiotics, with the yeast Saccharomyces boulardii being one such option.
Objectives: The primary objective was to assess the efficacy and safety of Saccharomyces boulardii in the treatment of acute GE 
in the paediatric population.
Method: Major electronic databases were searched from April 2014 to January 2015. Additional literature was obtained through 
hand-searching and reviewing of reference lists of articles and other systematic reviews. Randomised controlled trials (RCTs) in a 
hospital setting, involving participants < 16 years were used as the data source. Two reviewers independently screened studies 
for eligibility, assessed study quality and performed data extraction. Review Manager 5 was used to analyse data and a random-
effects model of meta-analysis was applied owing to heterogeneity.
Results: Ten of 190 articles were selected for final inclusion. A meta-analysis of five of the included studies showed that 
Saccharomyces boulardii compared with the control significantly shortened the duration of diarrhoea (in days) (MD –0.57, 95% CI 
–0.83 to –0.30, p < 0.0001), but there was no difference between groups regarding time to achieving formed stools. No adverse 
effects were reported. The GRADE tool assessed overall methodological quality as moderate.
Conclusion: Saccharomyces boulardii showed a potential benefit in treating acute GE in the paediatric patient. A dose of 250 mg 
1–2 times per day for up to 5 days showed some benefit and appears safe. Larger, rigorous RCTs are needed to investigate the 
efficacy and safety of Saccharomyces boulardii in order to offer specific treatment guidelines.
Trial registration: CRD42014009913.
Keywords: gastroenteritis, paediatric, randomised controlled trial, Saccharomyces boulardii
Introduction
Despite being a symptom known to be preventable and 
treatable, gastroenteritis (GE) contributes 5–10% of the total 
deaths in the under-five age group.1–3 The World Health 
Organization (WHO) defines diarrhoea/GE as ‘the passage of 
three or more loose/liquid stools per day, or more frequent 
passage than is normal for the individual’.4 The consistency of 
stools, and not so much the number, is also important in 
diagnosing GE.4–8 GE infections may be caused by one of three 
organisms, i.e. bacterial, viral or parasitic,7–8 with rotavirus found 
to be responsible for 215 000 child deaths globally during 2013.4 
Approaches to curbing the impact of rotavirus-causing GE have 
been implemented and with some degree of success, i.e. 
increasing the number of vulnerable individuals who receive the 
rotavirus vaccine, increased protection against contracting GE-
causing infections by encouraging mothers to breastfeed, 
improving accessibility to clean water supplies and educating 
populations about the importance of hygiene.7–8
The bacteria that are found in the gastrointestinal tract are a 
complex ecosystem and able to coexist with the host, as long as 
a state of balance is maintained.5,6,9–14 However, during disruptions 
in this balanced state, clinical disorders and disease can result. 
Gastrointestinal disorders, one of which being all forms of GE, 
can result in an imbalance, with the goal of treatment being 
reinstating balance to the gut bacteria’s ecosystem.5,6,9–14
Probiotics have been identified as a possible treatment modality 
to restore beneficial gastrointestinal bacteria to their original 
balanced state.9–13 The efficacy of these microorganisms is known 
to be strain-specific, making it important for them to be defined 
by their genus, species and strain.6,9–11 Research has shown that 
the human gastrointestinal tract contains a heterogenous mix of 
1014 bacteria, of which < 0.1% is yeast.6,9–11
Saccharomyces cerevisiae variety boulardii, more commonly 
referred to as Saccharomyces boulardii, is a non-pathogenic yeast 
that is suitable for human consumption, having been used in the 
treatment of inflammatory bowel disorders and several types of 
GE.12,14–16 Saccharomyces boulardii’s action is threefold, i.e. 
luminal, trophic on intestinal mucosa and regulatory on the 
immune system.5,14,16–19 The site of action for Saccharomyces 
boulardii is most commonly the colon and the yeast probiotic 
has been shown to survive passage to its target organ.5,14,16–19 
Most of the Saccharomyces strains have been shown to work 
optimally at temperatures between 22  °C and 30  °C; 
Saccharomyces boulardii, however, is able to survive temperatures 
of up to 37  °C, and therefore able to survive human body 
temperatures. Saccharomyces boulardii in a lyophilised form is 
able to survive gastric acid and bile.5,14,16–19 Stool sampling tests 
have shown that levels of Saccharomyces boulardii can be 100 to 
1 000 times lower than the oral dose offered, indicating that 
much of the oral dose is destroyed, but surviving doses have 
been found to be effective.5,14,16–19 It is naturally resistant to 
antibiotics and proteolysis and able to survive in the competitive 
milieu of the intestinal tract. In human subjects, the concentration 
in the colon was found to be dose-dependent. When 
Saccharomyces boulardii was given to healthy subjects at doses 
 
used therapeutically (1 to 2 x 1010/d), colonic levels were found to 
be 2 x 108/gram stool. Furthermore, when offered orally, 
Saccharomyces boulardii was able to achieve steady-state 
concentrations within 3 days and was only cleared within 3–
5 days after it had been discontinued. It has also demonstrated 
an ability to coexist and thrive in the presence of other agents, 
e.g. psyllium fibre increased Saccharomyces boulardii levels by 
22%.5,14,16–19
Probiotics (multiple single strains) with potentially multiple 
mechanisms of action14 were found to reduce the associated risk 
of acute GE (AGE) in children, with the effect dependent on the 
age of the host and the genera of the strain used.20 Saccharomyces 
boulardii specifically was shown to result in quicker GE resolution 
than that displayed by control groups.21 This yeast probiotic has 
the potential to be the sole or adjunct treatment in treating AGE, 
but, owing to research bias and confounding in documented 
studies, it remains difficult to develop guidelines on its role in 
managing AGE. As a result, our aim is to provide a systematic 
review of published studies, specifically assessing the efficacy 
and safety of Saccharomyces boulardii in the treatment of AGE in 
the paediatric population.
Methods
This project is registered with the Prospective Register of 
Ongoing Systematic Reviews (PROSPERO), trial registration 
number CRD42014009913.
Information sources and searches
A comprehensive literature search of the following electronic 
databases was conducted: Medline (accessed via PubMed); 
EBSCO host, including Academic Search Premier, Cumulative 
Index to Nursing and Allied Health Literature (CINAHL), Africa 
Wide and CAB Abstracts; Cochrane Library, which includes the 
Cochrane Databases of Systematic Reviews (CDSR, Cochrane 
Reviews), Cochrane Central Register of Controlled Trials 
(CENTRAL; Clinical Trials), Databases of Abstracts of Reviews of 
Effects (DARE; Other Reviews); ISI Web of Knowledge – Web of 
Science; Scopus (abstract and citation database of peer-reviewed 
literature); ProQuest Medical Library; Science Direct; and SABINET 
(South African Bibliographic Information Network). Additional 
literature was obtained through hand-searching and reviewing 
of reference lists of articles and other systematic reviews.
The final search string used was: (probiotic OR Saccharomyces 
boulardii) AND (diarrh* OR gastroent*) AND (clinical trial* OR 
randomized control trial* OR random allocation OR placebo* OR 
random research OR comparative OR evaluation stud* OR follow 
up OR prospective* OR control* OR volunteer* OR single mask* 
OR double mask* OR treble mask* OR tripl* mask* OR double 
mask* OR treble mask* OR tripl* mask* OR single-blind OR 
double-blind OR treble blind OR tripl* blind). The only limits 
applied whilst using this search string were human and child 
(birth to 18 years), and therefore foreign-language articles were 
included. This search string was applied across all databases 
mentioned above, with all searches completed up to January 27, 
2015.
Inclusion criteria
Only randomised controlled trials (RCTs) involving human 
participants and investigating the efficacy and safety of 
Saccharomyces boulardii were considered. Trials were included 
regardless of the lack of blinding or placebo treatment. All other 
study designs were excluded. Infants and paediatric patients, 
aged between 0 and 16 years, had to be admitted to a hospital 
setting with a diagnosis of AGE (≥ 3 unformed stools in the last 
24 h and of ≤ 48 h duration). Studies including patients with the 
following characteristics were excluded: chronic illnesses, under-
nutrition, severe dehydration, known allergies, recent history of 
use of one or a combination of probiotics, antibiotics and anti-
diarrhoea medication. Only studies using Saccharomyces 
boulardii as the intervention were included. Any study in which 
the Saccharomyces boulardii intervention was confounded by 
another intervention and without a proper control was excluded. 
Use of other strains of Saccharomyces (as the intervention) was 
not included.
Outcomes
The interventions and outcome measures were identified by the 
authors based on clinical relevance (see Table 1) with modifiers 
and confounders decided a priori.
Data collection and extraction
Preliminary screening was conducted by one reviewer (MP) and 
articles that were clearly non-relevant to the current systematic 
review were filtered out of the search pool (e.g. non RCTs; multi-
species trials, studies not related to AGE). Pre-piloted study 
eligibility forms were then used by each of the two identified 
reviewers (MP and EV), article titles and abstracts were screened, 
consensus was obtained for all articles and clearly non-relevant 
articles were removed. Thereafter, a pre-piloted standardised 
data extraction form was used by each of the two reviewers (MP 
and EV) to independently extract data from the full text articles 
used in this systematic review. Any disagreements were resolved 
by discussion between the two reviewers (MP and EV), with 
assistance from the rest of the author team as necessary. All 
excluded studies were listed, each with reasons for exclusion.
Risk-of-bias assessment
The domains of the methodology assessed were sequence 
generation, allocation concealment, blinding, incomplete 
outcome data, selective outcome reporting and other potential 
sources to affect validity.22–24 Assessment was done using the 
Table 1: Outcome measures and modifiers/confounders
Outcome measures Confounders
Primary outcomes Secondary outcomes
•  Duration of diarrhoea in days
•  Mean number of stools passed per day
•  Mean number of episodes of diarrhoea at follow up
•  Frequency of diarrhoea at start, mid-point, end of 
intervention
•  Stool frequency
•  Changes in stool consistency post intervention
•  Duration of hospital stay in days •  Active ingredients offered concurrently with the 
intervention (e.g. antibiotics)
•  The intervention being offered as part of a cocktail 
of treatment
•  Differences in dosages offered and method of 
administration
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Cochrane risk-of-bias assessment tool, where the judgement of 
‘yes’ was indicative of low risk of bias, ‘no’ was indicative of high 
risk of bias, and ‘unclear’ was indicative of uncertain risk of bias.22–
24 This was done by two independent reviewers (MP and EV) and 
disagreements between each of the reviewers’ judgements were 
resolved by discussion, with assistance from the rest of the 
author team as necessary.
Grading the body of evidence
The Grades of Recommendations, Assessment, Development 
and Evaluation (GRADE) system for rating overall quality of 
evidence for the most relevant outcomes was applied.22–24 The 
quality of evidence was further categorised as either high 
(confident that the true effect lies close to that of the estimated 
effect), moderate (moderately confident in the effect estimate), 
low (confidence in the effect estimate is limited) and very low 
(very little confidence in the effect estimate).22–24
Statistical analysis
All dichotomous data resulted in the following information 
being extracted from each treatment group: the number of 
participants with the event and the total number of participants. 
Risk ratios (RRs) were calculated for all dichotomous data. All 
continuous data resulted in the following information being 
extracted from each treatment group: the arithmetic mean, 
standard deviation (SD) and number of participants. The SD was 
calculated using the 95% confidence interval (CI) and mean 
differences (MDs) were calculated for continuous data where 
applicable. Assessment of heterogeneity was achieved through 
the visual inspection of forest plots.22,23 CIs were assessed and 
considered to have statistical heterogeneity if there was poor 
overlap of the results of individual studies. A chi-square test for 
heterogeneity (significance level p < 0.1) was conducted and the 
I2 statistic calculated.
Funnel plots are usually used to explore the possibility of small-
study bias.22,23 Tests for funnel plot asymmetry should only be 
used when there are a least 10 studies included in a meta-
analysis, as fewer studies would result in the power of the tests 
being too low to identify chance versus real asymmetry.22,23 Since 
a meta-analysis of 10 or more studies was not undertaken in this 
systematic review, funnel plots were not used to assess 
publication bias.
Results
Ten studies25–34 met the inclusion criteria and were included in 
this systematic review (see Figure 1). The 10 included studies25–34 
were published between 2006 and 2013. Important information 
concerning these studies can be found in Table 2. A total of 1 401 
participants were included from the combined 10 studies, with 
the smallest study30 involving 27 participants and the largest 
study31 involving 480 participants. Included studies were 
conducted in a hospital setting, but in multiple global locations, 
i.e. one in Pakistan,27 two in India,28,32 one in Brazil,29 one in 
Myanmar34 and five in different hospitals within Turkey.25,26,30,31,33
All 10 included studies adopted a study design that included 
both an intervention and control/placebo group, being 
monitored in parallel. The intervention arm consisted of  ≥  1 
intervention, but with Saccharomyces boulardii always being 
used as an independent intervention. Across all 10 studies, 
Saccharomyces boulardii was used at a dose ranging from 200 
mg29 to 250 mg25,27,28,30–34 with only one study26 offering the yeast 
probiotic at a slightly higher dose of 282.5  mg. In terms of 
frequency of treatment, 50% of studies offered the intervention 
dose once per day26,28,29,31,33 and 50% offered the intervention 
dose twice per day.25,27,30,32,34
Most studies25,28,29,31–34 considered the first five days as the ‘active’ 
treatment days, with one study27 using six days as the active 
treatment days. Only one study30 required the intervention to be 
implemented over a seven-day period. One study26 did not 
specify the minimum ‘active’ treatment phase but provided 
information on the mean duration time of GE in all study groups 
of (5.9 ± 2.0) days. Of all the included studies, only one27 followed 
participants for two months post discharge to assess incidence 
of GE episodes post intervention.
Not all included studies indicated or implemented the use of a 
placebo in their study designs, i.e. six studies25–28,31,34 did not 
describe or make use of a placebo, whilst the remaining four 
studies29,30,32,33 mentioned/described the placebo treatment 
used.
The four studies that described use of a placebo did so in different 
ways, i.e. one study33 offered both the intervention and an 
identical-looking placebo diluted in water or juice (as advised by 
the manufacturer); one study30 offered both the intervention and 
placebo dissolved in water; one study32 offered both the 
intervention and placebo in identical packets mixed with puffed 
rice powder; and one study29 offered both the intervention and 
placebo in capsule form, prepared by a faculty pharmacy.
Methodological quality
Random sequence generation was found to be adequate in 4 of 
the 10 studies.25,28,31,34 No studies were found to be at high risk of 
bias in this domain. Adequate allocation concealment was 
achieved in 2 of the 10 studies,29,32 with 2 studies25,27 classified as 
high risk of bias. The blinding of participants and personnel was 
found to be adequate in 4 of the 10 studies.29,30,32,33 Three 
studies25,26,34 posed a high risk to blinding practices and the 
remaining three studies27,28,31 did not provide enough details to 
be totally clear about bias infringements in this domain.
In total, 50% of the studies26,27,30,31,34 did not clearly indicate how 
blinding of outcome assessment was guaranteed. The remaining 
studies consisted of only one study33 that did not provide for 
adequate blinding of this domain and four studies25,28,29,32 
achieving adequate blinding. Six studies25,27–29,31,32 provided 
enough information to be considered to have adequate 
prevention of attrition bias. Only eight studies25–29,32–34 clearly 
reported on all outcomes initially mentioned.
Sources of funding could possibly play a role as a potential 
source of bias: two of the included studies27,30 were funded and 
supported by pharmaceutical companies, with one study30 
declaring no conflict of interest in relation to the study. One 
study28 acknowledged receiving financial support from a 
university affiliated with the hospital where the study was 
conducted. Another study29 reported support from a government 
council involved with scientific and technological development. 
Some 50% of the included studies25,26,31–33 did not disclose any 
information about source of funding or financial support 
received. However, one of these studies32 made a simple 
declaration that no conflict of interest and no funding were 
received for the study. The one remaining study34 was the only 
study where authors commented that it was completed with a 
very limited budget owing to there being no involvement of the 
company commercialising the yeast probiotic that was used in 
the interventional arm. Other areas of bias did not appear to be a 
60 South African Journal of Clinical Nutrition 2019; 32(3):58–69
 
Summary of main results
Primary outcomes: All of the included studies investigated the 
efficacy of Saccharomyces boulardii on GE caused by rotavirus 
but reported their findings in somewhat different ways. Seven 
studies26–28,31–34 reported duration of diarrhoea (in days), whilst 
one study28 reported the outcome as recovery from loose 
motions. Five studies26,28,31–33 were pooled in a random effects 
meta-analysis which showed that Saccharomyces boulardii 
significantly shortened the duration of diarrhoea (in days), 
compared with the control or placebo group (MD –0.57; 95% CI 
–0.83 to –0.30; n = 548 children; five studies). Furthermore, there 
concern in eight of the included studies25–27,29,30,32–34 and was 
considered adequate (see Figure 2).
GRADE assessment
GRADEpro software (http://www.gradepro.org) was used to 
assess overall methodological quality as follows: duration of 
diarrhoea (rated moderate); mean number of stools per day (only 
one study of low quality); frequency of diarrhoea (one study but 
of high quality); number having <3 stools per day (one study of 
moderate quality); and duration of hospital stay (two studies 
with evidence rated as low). A summary of findings table was 
generated (see Table 3).
Figure 1: PRISMA study flow diagram.
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was no significant heterogeneity detected between the trials 
(tau2 = 0.00; chi2 = 1.57; df = 4; p = 0.81; I2 = 0%) (see Figure 3).
Although two studies27,34 reported the mean duration of 
diarrhoea without the corresponding SDs, and therefore could 
not be included in the above meta-analysis, the study authors 
reported that Saccharomyces boulardii significantly shortened 
the duration of diarrhoea (in days), compared with the control 
group in both studies, i.e. one study27 (MD –1.2 (3.6 versus 4.8); n 
= 100 children; p = 0.001); and one study34 (MD –1.6 (3.08 versus 
4.68); n = 100 children; p < 0.05).
Three studies27,30,32 could not be used in the above meta-analysis 
owing to limited information; one research group27 did report 
that use of Saccharomyces boulardii offered statistically significant 
effects on the number of stools per day compared with the 
control group for Day 3 (MD –1.6 (2.8 versus 4.4); p = 0.01) and 
Day 6 (MD –1.7 (1.6 versus 3.3); p = 0.001), but not for Day 0 (MD 
(9.5 versus 8.8); p = 0.37). Results from the remaining study30 
showed a significant difference in the mean number of stools per 
day between the Saccharomyces boulardii group and the control 
group for Day 1 (MD –0.86; 95% CI –1.15 to –0.57), Day 2 (MD –
1.21; 95% CI –1.49 to –0.93), Day 3 (MD –1.68; 95% CI –1.93 to –
1.43) and Day 4 (MD –1.38; 95% CI –1.65 to –1.11), but there was 
no difference on Day 0 (MD 0.31, 95% CI –0.06 to 0.68). Overall, 
the pooled effect size for the duration of treatment of AGE in this 
study favoured the Saccharomyces boulardii group (p = 0.001).
Billoo et al.27 reported on the mean number of episodes of 
diarrhoea after Month 1 and Month 2 but there were no SDs 
reported. Saccharomyces boulardii was found to significantly 
shorten the mean number of episodes of diarrhoea compared 
with the control group for both Month 1 (MD –0.44 (0.2 versus 
0.64); n = 100 children; p = 0.001) and Month 2 (MD –0.24 (0.32 
versus 0.56); n = 100 children; p = 0.04).
Another study29 reported the number of children having 
diarrhoea on each day after starting the intervention and the 
results show that Saccharomyces boulardii significantly reduced 
the risk of diarrhoea compared with the control group for Day 2 
(RR 0.54; 95% CI 0.42 to 0.70; n = 176 children) and Day 3 (RR 0.54; 
95% CI 0.38 to 0.77; n = 176 children) but not on Day 1 (RR 0.96; 
95% CI 0.87 to 1.05; n = 176 children). Overall, the effect of 
Saccharomyces boulardii for the first three days of treatment did 
not demonstrate superiority over the control (p = 0.19).
The authors Htwe et al.34 reported on the number of children 
having < 3 stools per day after starting the intervention and the 
results show that significantly more children were having < 3 
stools per day in the Saccharomyces boulardii group (n = 50) 
compared with the control group (n = 50) on Day 2 (RR 1.80; 95% 
CI 1.10 to 2.95), Day 3 (RR 1.39; 95% CI 1.05 to 1.85), and Day 4 (RR 
1.23; 95% CI 1.05 to 1.44). On Day 1, none of the children had < 3 
stools per day in either group. On Day 6 and Day 7, all the children 
had < 3 stools per day. On Day 5, there was no difference in the 
number of children having < 3 stools per day in the two groups 
(RR 1.04; 95% CI 0.97 to 1.11). Although this analysis appeared to 
moderately favour the Saccharomyces boulardii group, it was not 
statistically significant (p = 0.11).
These same authors34 reported on the number of children having 
solid stools per day after starting intervention and the results 
show that significantly more children were having solid stools in 
the Saccharomyces boulardii group (n = 50) compared with the 
control group (n = 50) on Day 2 (RR 3.00; 95% CI 0.32 to 27.87), 
Day 3 (RR 3.17; 95% CI 1.89 to 5.31), Day 4 (RR 1.63; 95% CI 1.30 to 
2.06) and Day 5 (RR 1.25; 95% CI 1.08 to 1.44). On Day 1, none of 
the children had solid stools in either group. On Day 7, all the 
children had solid stools. On Day 6, there was no difference in the 
number of children having solid stools between the two groups 
(RR 1.04; 95% CI 0.97 to 1.11). Although the results appeared to 
favour the Saccharomyces boulardii group, this was not 
statistically significant (p = 0.06).
In addition to the above, one other primary outcome of the 
current systematic review was to investigate the safety of use of 
this yeast probiotic in the paediatric hospitalised patient. None 
of the included studies reported on any significant side effects 
associated with Saccharomyces boulardii use.
Secondary outcomes: Two studies31,33 reported on the duration 
of hospital stay (in days) and their results were combined in a 
meta-analysis that resulted in significant statistical heterogeneity 
(tau2 = 1.55; chi2 = 18.94; df = 1; p < 0.0001; I2 = 95%) (see 
Figure  4).
None of the 10 studies evaluated other outcomes (e.g. cost-
effectiveness, optimal dosing and delivery method, frequency/
duration of treatment, timing of delivery of Saccharomyces 
boulardii).
Discussion
In this systematic review, we set out to assess the effectiveness 
and safety of Saccharomyces boulardii in the management of 
AGE in the paediatric hospitalised population. Like the current 
systematic review, other researchers like Szajewska et al. (2007),21 
McFarland (2010),16 Allen et al. (2010)14 and Pan et al. (2012)35 
have attempted to review and possibly put forward treatment 
guidelines for the use of Saccharomyces boulardii in the 
management of GE, but often in a mixed population of both 
adult and paediatric participants, whilst this review focused 
exclusively on the latter.
Except for the study setting not being a hospital, the systematic 
review conducted by Szajewska et al. (2007)21 is the closest match 
to the inclusion criteria of the current systematic review. These 
authors21 conducted a systematic review of only RCTs to test the 
effectiveness of Saccharomyces boulardii in treating AGE in 
children. Five RCTs involving 619 participants were included. The 
combined data showed that Saccharomyces boulardii significantly 
reduced the duration of diarrhoea when compared with the 
control arm. Using a fixed and random effects model, this yeast 
probiotic still produced a mean difference of –1.1 days (95% CI –
1.2 to –0.8). Although a smaller study sample (n = 548) and a 
smaller mean difference of –0.57 days (95% CI: –0.83 to –0.30), 
the current systematic review also produced results in favour of 
use of Saccharomyces boulardii to treat AGE, but specifically in 
the paediatric patient. Significant changes in GE experienced by 
the Saccharomyces boulardii group versus the control group 
were noted on Day 3, in addition to Day 6 and Day 7, similar to 
results reported by McFarland (2010).16 Szajewska et al.21 also 
reported than in one RCT study (n = 88) the risk of diarrhoea 
lasting > 7 days was significantly reduced in the Saccharomyces 
boulardii versus the control group (RR 0.25; 95% CI 0.08 to 0.83; 
number needed to treat = 5, 95% CI 3 to 20). Such results pointed 
in the direction of Saccharomyces boulardii displaying moderate 
clinical benefit in otherwise healthy infants and children with 
AGE.
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Figure 2: Methodological quality graph: judgements on each methodological quality item presented as percentages for all included studies (n = 10).
The Cochrane Review carried out by Allen et al. (2010)14 was 
another systematic review aimed at assessing the effect and – 
like the current systematic review – safety of probiotics, including 
Saccharomyces boulardii, in treating GE. This review was much 
larger than the systematic reviews mentioned earlier as it 
included 63 studies with a combined 8 014 participants. Within 
this large pool of studies, 56 included infants and young children. 
The included studies took the form of either RCTs or quasi-RCTS 
that compared the effect of a specified probiotic with either a 
placebo/no probiotic in people with AGE. The overall result was 
indicative of probiotics (including Saccharomyces boulardii) 
having the ability to reduce the duration of GE. But similar to 
McFarland (2010),16 these authors14 also acknowledged 
challenges faced in conducting their systematic review. Included 
studies in their systematic review varied in their definitions of 
both AGE and AGE resolution, the studies were all undertaken in 
a wide range of different settings and there was variation in 
terms of the organism tested, dosage offered and participant 
characteristics. The authors14 concluded that if used alongside 
oral rehydration solution, probiotics (including Saccharomyces 
boulardii) appeared to be safe and have the potential to reduce 
AGE duration and reduce stool frequency.
The systematic review conducted by Pan et al. (2012)35 was 
similar to the current systematic review in that three of the 
studies27,33,34 included in the current systematic review also 
featured in their35 list of included studies. Similar to challenges 
experienced with the current systematic review, these authors 
also had difficulty retrieving suitable RCTs for inclusion, i.e. only 8 
included studies from a total pool of 678. These 8 studies 
included participants that ranged between the ages of 1 month 
up to 12  years, were all described as being randomised into 
either the Saccharomyces boulardii or the control (commercialised 
oral rehydration solution) group, received about the same 
dosage of Saccharomyces boulardii (500 mg/d) but with only two 
studies indicating smaller doses of Saccharomyces boulardii 
(250 mg/d) for participants < 12 months. All participants received 
the intervention for a period of 5–7  days, with only one study 
continuing to follow the participants up to Day 14. Although 
only 25% of the included studies reported on the cause of the 
GE, and not all studies were carried out in a hospital setting, the 
authors reported that the results of their meta-analysis showed 
that the Saccharomyces boulardii group was more effective than 
the control group in decreasing the following: duration of 
diarrhoea (MD –0.92, 95% CI –1.32 to –0.52), stool frequency on 
Day 3 (MD –1.92, 95% CI –1.63 to –0.95), Day 4 (MD –0.51, 95% CI 
–0.89 to –0.33), and Day 7 (MD –0.44, 95% CI –0.72 to –0.16), 
respectively. Despite only 25% of included studies indicating the 
cause of the diarrhoea in each of their studies, the authors 
concluded that Saccharomyces boulardii displayed therapeutic 
effects in treating children with AGE.
Safety of use of the yeast probiotic was the other primary 
outcome under investigation, and of the 10 included studies, 
only 1 study33 reported on a single participant complaining of 
‘meteorism’, which is defined as excess gas accumulating in the 
gastrointestinal system and causing abdominal distension.36 No 
additional information was provided by the authors and neither 
was there mention of the participant needing to be removed 
from the trial. Other than this reporting, no serious adverse 
reaction in the Saccharomyces boulardii group was registered 
during any of the included studies.
Overall, offering this unique yeast probiotic at a dose of 250 mg 
once to twice per day for up to 5–7  days has shown some 
statistically significant benefit in decreasing the duration of AGE. 
Although no statistical difference was noted between the groups 
with the number of days in hospital, the days to appearance of 
the first semi-formed stool were found to be fewer in the 
Saccharomyces boulardii group as compared with the control gro
up.9–12,14,19,28–32,34
Overall completeness and applicability of evidence
Any factor that disrupts the bowel’s multifaceted ecosystem can 
result in the development of gastrointestinal disease, with GE 
being one of the most documented symptoms. The difficulty this 
presents is that GE can be categorised in various ways, i.e. 
according to cause (e.g. bacterial, viral, parasitic),3,4,6 or by severity 
(e.g. mild, moderate and severe).3,4,6 This systematic review was 
very specific as it aimed to include only those studies addressing 
mild–moderate GE caused by the rotavirus. In addition, subjects 
needed to be between 0 and 16 years, be in a generally healthy 
condition with no other co-morbidities and qualify for 
hospitalisation. The addition of studies investigating the effects 
of Saccharomyces boulardii only made this a very challenging 
search for supporting studies. Reviewers identified 10 RCTs 
involving a combined 1 401 participants between the ages of 0 
and 16 years for inclusion in this systematic review.
The study settings within which each of the included studies 
took place were in many different countries across the globe (i.e. 
Pakistan, India, Brazil, Myanmar and Turkey). Aside from varied 
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Table 3: Summary of findings table using GRADE: Saccharomyces boulardii compared with control or placebo for AGE
Notes: Patient or population: patients with AGE.
Settings: in paediatric, hospitalised patients.
Intervention: Saccharomyces boulardii.
Comparison: control or placebo.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.
The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence:
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Selection bias (Kurugol 2005, Erdogan 2012, Burande 2013, Dalgic 2011); reporting bias (Kurugol 2005, Erdogan 2012); blinding (Erdogan 2012, 
Burande 2013, Dalgic 2011); other bias (Dalgic 2011, Riaz 2013).
2No downgrading for inconsistency as: four of five studies have CIs that overlap meaning that any variation in the size of effect is more likely a result of 
chance; I2 value of 0% indicating no heterogeneity; non-significant p-value.
3Downgrading for inconsistency as only Day 0 out of 5 days intercepted the line of no effect meaning that any variation in the size of effect is not due 
to chance; I2 value is very high 95.3% indicating heterogeneity; very low p-value (< 0.00001).
4Downgrading for inconsistency as the forest plot for this outcome shows that of each of the three days of assessment, only results for Day 1 overlap 
with the line of no effect; the overall test for heterogeneity showed a high I2 of 96% and a very low p-value (< 0.00001).
5No downgrading as this outcome shows a wide CI with the effect on the side favouring benefit, a large number of events (148+200) and a large 
sample size (270+258).
6Corrêa 2011: An RR of 0.66 indicating that the Saccharomyces boulardii group was 34% more likely to experience fewer stools per day versus the 
control group.
7Htwe 2008: not all CIs overlap the line of no effect; I2 value quite high at 95% and accompanied by a very low p-value (< 0.00001).
8Htwe 2008: Overall, this analysis showed a RR (1.13) indicating that the Saccharomyces boulardii group was 1.13 times more likely to experience < 3 
stools per day quicker than the control group.
9Only Dalgic 2011 and Kurugol 2005 assessed impact of Saccharomyces boulardii on length of hospital stay.
10Dalgic 2011: selection bias was unclear as no information was given on how allocation concealment was achieved. Reporting bias as no mention 
is made regarding the training of parents for reporting of symptoms like ‘appearance of stools’, ‘watery GE’, ‘GE’. Other bias: 480 participants were 
recruited and all 480 were reported to have completed the study, with no withdrawals, exclusions or loss to follow-up?
11Downgrading for inconsistency as neither study truly overlaps with the line of no effect meaning that any variation in the size of effect is not due to 
chance; I2 value is very high 95% indicating heterogeneity; very low p-value (< 0.0001).
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Figure 3: Forest plot of trials comparing Saccharomyces boulardii versus control in children with gastroenteritis: difference in duration of diarrhoea 
(in days).
Figure 4: Forest plot: duration of hospital stay (in days, Saccharomyces boulardii versus control).
geographical settings, the included studies also included 
participants that were from varied backgrounds, of differing 
socioeconomic status, with different research resources, different 
research teams and therefore varied methodological quality 
standards. One of the secondary outcomes of the current 
systematic review was to investigate the effect of Saccharomyces 
boulardii on the days of hospitalisation. Of the 10 included 
studies, only 3 studies25,31,33 reported on this outcome and each 
with a different result.
Quality of evidence
The 10 studies included in this review lacked meticulousness 
when it came to methodological quality. All 10 trials met the 
prerequisite of being RCTs. When judgement concerning each 
methodological quality item for each included study was 
undertaken, shortcomings across some of the domains for some 
of the studies were noted. Selection bias was clearly prevented in 
four studies25,28,31,34 as simple randomisation methods were 
described, i.e. computer-generated random numbers,28,31 
according to identification numbers25 and simple alternated 
allocation to treatment and control groups.34 The remaining six 
studies26,27,29,30,32,33 reported carrying out randomisation but 
details on how this was achieved were unclear.
The quality of the individual included studies ranged between 
low and moderate, with unclear risk of bias displayed for 
especially the first four domains, i.e. random sequence 
generation, allocation concealment, blinding of participants/
personnel and blinding of outcome assessment (see Figure 2). 
Some of the results for some outcomes showed clear differences 
between groups within single studies. However, the manner in 
which outcomes were reported (i.e. number of stools per day, 
days to < 3 stools per day, mean number of stools) resulted in 
only one meta-analysis being done.
Potential biases in overview process
One of the biggest ‘threats’ to systematic reviews is publication 
bias, defined as ‘the publication or non-publication of research 
findings, depending on the nature and direction of results’.22,23 As 
a result, this would impact on the ‘true’ nature of the research 
topic under investigation. Although an exhaustive electronic 
search strategy was employed in this systematic review, there is 
always the possibility that applicable research papers could have 
been missed or overlooked during various stages of the search 
and selection process. The use of two reviewers (MP and EV) 
independently assessing studies for inclusion in this systematic 
review was an additional measure to address this form of bias.
Strengths and limitations of this review
Although only 10 studies successfully met the predetermined 
inclusion criteria, this led to a more appropriate comparison, and 
therefore pooling of results between the intervention and 
control groups of each individual study. Although foreign-
language studies were excluded from this review, all potentially 
eligible studies reported in languages other than English were 
documented for future assessment. Of the latter only one study 
appeared to be possibly relevant to this investigation.
Lastly, the authors of this systematic review were able to identify 
and use RCTs that met the predefined inclusion criteria but could 
not control for the different geographical settings in which each 
of these trials was conducted and their influence on the results of 
this review.
Conclusions
Overall, the results indicate that Saccharomyces boulardii 
shortened the duration of AGE caused by rotavirus (in days) 
when compared with the control/placebo group, with the 
included studies displaying little/no heterogeneity. In addition, 
no adverse effects were associated with the use of this yeast 
probiotic in treating AGE in otherwise healthy children. Therefore, 
the results of the current systematic review indicate that there is 
a potential benefit associated with the use of Saccharomyces 
boulardii to treat AGE in the paediatric patient.
However, owing to factors such as small sample sizes, unclear 
and inconsistent quality of methodology, and reporting bias 
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owing to source of funding and support, a definitive conclusion 
and recommendation for the use of a specific probiotic like 
Saccharomyces boulardii to be used as treatment or treatment 
adjunct for AGE in the paediatric hospitalised patient cannot yet 
be made. Future research initiatives investigating the subject of 
the benefits/harm associated with the use of Saccharomyces 
boulardii must therefore endeavour to consist of larger RCTs 
which: minimise heterogeneity associated with study 
participants enrolled, clearly predefine aetiologies, e.g. GE or 
AGE, minimise methodological variability (e.g. blinding), 
standardise the presentation in which the intervention is offered, 
and conduct single-strain probiotic investigations. In addition, 
secondary outcomes like length of hospital stay and cost-
effectiveness can also be investigated.
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